Anttila S, Luostarinen L, Hirvonen A, Elovaara E, Karjalainen A, Nurminen T, Hayes J D, Vainio H, Ketterer B
Finnish Institute of Occupational Health, Helsinki.
Cancer Res. 1995 Aug 1;55(15):3305-9.
To characterize the relative roles of glutathione S-transferases (GST) M1 and M3 in the susceptibility to lung cancer, the pulmonary expression of GSTM3 was quantified immunochemically and related to the GSTM1 genotype in 100 lung cancer patients. Among active smokers and recent ex-smokers (for 6 years or less), parenchymal GSTM3 expression was lower in patients with a homozygous GSTM1 null genotype than in those who were GSTM1 positive and had similar smoking habits (P < 0.001 and P = 0.004, respectively). However, in long-term ex-smokers (for 15 years or longer) GSTM3 was not affected by the GSTM1 genotype. Among active smokers and recent ex-smokers who were homozygous GSTM1 null, those with a definite or probable exposure to asbestos expressed GSTM3 at significantly higher levels than those for whom it was unlikely (P = 0.04). A similar effect of the homozygous GSTM1 null genotype on GSTM3 expression was not detected in the bronchial epithelium when GSTM3 was visualized immunohistochemically. Different mechanisms may result in an increased risk of either squamous cell or adenocarcinomas in patients with the homozygous GSTM1 null genotype. Low expression of GSTM3 due to smoking in the parenchymal lung of GSTM1 null individuals can theoretically favor the development of adenocarcinoma. Our data indicated a predominance of this tumor type in patients with low expression of GSTM3.
为了明确谷胱甘肽S-转移酶(GST)M1和M3在肺癌易感性中的相对作用,我们采用免疫化学方法对100例肺癌患者的肺组织中GSTM3的表达进行了定量分析,并将其与GSTM1基因型相关联。在现吸烟者和近期戒烟者(戒烟6年及以内)中,纯合GSTM1无效基因型患者的实质组织中GSTM3表达低于具有相似吸烟习惯的GSTM1阳性患者(分别为P < 0.001和P = 0.004)。然而,在长期戒烟者(戒烟15年及以上)中,GSTM3不受GSTM1基因型的影响。在纯合GSTM1无效基因型的现吸烟者和近期戒烟者中,明确或可能接触石棉的患者GSTM3表达水平显著高于不太可能接触石棉的患者(P = 0.04)。当通过免疫组织化学观察GSTM3时,在支气管上皮中未检测到纯合GSTM1无效基因型对GSTM3表达有类似影响。纯合GSTM1无效基因型的患者患鳞状细胞癌或腺癌的风险增加可能是由不同机制导致的。GSTM1无效个体肺实质中因吸烟导致的GSTM3低表达理论上有利于腺癌的发生。我们的数据表明,GSTM3低表达的患者中这种肿瘤类型占优势。